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Abstract
Sirtuin 1 (SIRT1) activity is neuroprotective, and we have recently demonstrated its role in the retrograde degenerative
process in motoneurons (MNs) in the spinal cord of rats after peripheral nerve root avulsion (RA) injury. SIRT2 has been
suggested to exert effects opposite those of SIRT1; however, its roles in neurodegeneration and neuron response after
nerve injury remain unclear. Here we compared the neuroprotective potentials of SIRT1 activation and SIRT2 inhibition
in a mouse model of hypoglossal nerve axotomy. This injury induced a reduction of around half MN population within
the hypoglossal nucleus by a non-apoptotic neurodegenerative process triggered by endoplasmic reticulum (ER)
stress that resulted in activation of the unfolded protein response mediated by IRE1α and XBP1 by 21 days post injury.
Both SIRT1 activation with NeuroHeal and SIRT2 inhibition with AK7 protected NSC-34 motor neuron-like cells against
ER stress in vitro. In agreement with the in vitro results, NeuroHeal treatment or SIRT1 overexpression was
neuroprotective of axotomized hypoglossal MNs in a transgenic mouse model. In contrast, AK7 treatment or SIRT2
genetic depletion in mice inhibited damaged MN survival. To resolve the in vitro/in vivo discrepancies, we used an
organotypic spinal cord culture system that preserves glial cells. In this system, AK7 treatment of ER-stressed
organotypic cultures was detrimental for MNs and increased microglial nuclear factor-κB and the consequent
transcription of cytotoxic pro-inﬂammatory factors similarly. The results highlight the importance of glial cells in
determining the neuroprotective impact of any treatment.
Introduction
Axonopathy is a common early characteristic of the
neurodegenerative processes in the central nervous sys-
tem1. Axon degeneration often leads to retrograde
neuronal cell death or atrophy and the progressive and
permanent loss of vital neuronal functions. Deciphering
the signaling involved is necessary for the development
of effective neuroprotectants that are greatly needed in
the clinics. Transgenic models of neurodegenerative
diseases are broadly used, but shed light on only single
pieces of the puzzle. Non-transgenic models of neuro-
degeneration also yield valuable information regarding
the “naturally occurring processes” after neuronal
soma–axon disconnection. By exploiting the anatomical
and technical advantages of several axotomized models,
it has been shown that multiple signaling programs
operate in parallel in neuronal soma during the
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retrograde neurodegenerative process that does not end
in apoptosis2, 3.
This knowledge has been useful in the discovery of
effective neuroprotectants such as the new discovered
drug combination NeuroHeal (NH)4, 5. NH was dis-
covered using unbiased proteomic data, systems biology,
and artiﬁcial neural networks from two models that
represented pure regenerative and pure neurodegenera-
tive conditions after peripheral nerve distal axotomy or
root avulsion (RA) injuries, respectively. The data were
used to build up bona ﬁde state-speciﬁc molecular maps,
and mathematical models were used to screen databases
of drugs to identify putatively neuroprotective combina-
tions. NH is a combination of acamprosate and ribavirin,
two repurposed drugs with well-described pharmacoki-
netics and pharmacodynamics proﬁles that have no ser-
ious adverse effects.
Activation of sirtuin 1 (SIRT1) was shown to be
necessary for the neuroprotective action of NH after RA5.
Sirtuins constitute a highly conserved family of deacety-
lases that regulate cellular homeostasis6. Seven homologs
of yeast Sir2 (SIRT1–7) that have a conserved catalytic
domain have been identiﬁed in mammals7. Among them,
SIRT1 and SIRT2 have been targeted in the design of
neuroprotectants for the treatment of degenerative con-
ditions and traumatic injuries8. SIRT1 regulates a number
of pathways associated with normal metabolism and
functioning of individual organs in mammals9, including
those involving histone 3, p53, and nuclear factor-κB (NF-
κB) among others10. SIRT2 regulates cell cycle and gen-
ome instability in part acting as a histone deacetylase with
a preference for histone H4 lysine 1611. It is also the most
abundant sirtuin in the brain where it deacetylates α-
tubulin at lysine 40 contributing in microtubule dynamic
regulation12.
Both SIRT1 activation and SIRT2 inhibition have been
identiﬁed as good strategies for neurodegenerative dis-
eases. In the present work, we aimed to validate whether
these strategies could be extended to disconnected neu-
rons using a model of axotomy of the hypoglossal nuclei,
which contain highly vulnerable cranial MNs13–15 that
differ in their properties from the spinal MNs16.
Results
In order to evaluate how SIRT1 and SIRT2 function in
neuroprotection of MNs after proximal nerve injury we
chose to use the hypoglossal axotomy model17 (Fig. 1a).
We ﬁrst characterized the pace of MN cell death at the
hypoglossal nucleus over time post injury. We observed
that the process slowly proceeded with the number of
MNs reduced by 48.72 ± 2.2% after 21 days post injury
(dpi) (Fig. 1a). Apoptotic hallmarks, such as activation of
caspase-3 or apoptosis-inducing factor (AIF) nucleariza-
tion, were not observed, although MNs were degenerating
as revealed by Fluoro-Jade C staining at 7 dpi (Fig. 1b).
These observations were similar to those in our previously
reported model of nerve RA in rat18. To explore whether
there was activation of endoplasmic reticulum (ER) stress
in the hypoglossal axotomy model, we analyzed the
expression of target genes of the unfolded protein
response (UPR) activated after ER stress, as Chop, Grp78,
Xbp1, and its spliced version (Xbp1s), as well as the
activation of three main branches of UPR, PKR-like ER
kinase (PERK), inositol-requiring enzyme 1α (IRE1α), and
activating transcription factor 6 (ATF6), by western blot.
The only gene found overexpressed was the spliced form
of Xbp1 at 3 dpi (Fig. 1c). The apparition of this form after
ER stress depends on the activation of IRE1α, which
autophosphorylates, dimerizes, and acquires ribonuclease
activity, leading to splicing of the mRNA encoding the X-
box binding protein XBP119. In agreement, we observed
that the phosphorylated dimer of IRE1α was more
abundant and the ratio of spliced to unspliced XBP1 was
higher in animals subjected to hypoglossal axotomy than
controls by western blot (Fig. 1d). However, there were
not activation of the UPR branches ATF6 or PERK after 3
dpi characterized by the presence of the 50-kDa-cleaved
fragment of ATF6 and the increase of the phosphorylated
isoform of PERK, respectively (Fig. 1d). These results
suggest that the neurodegenerative pathway involved in
cranial MN death is non-apoptotic and presents some
hallmarks for the presence of ER stress, similar to the
process that occurs after RA in rats were only IRE1α
activation was also found.
Activation of SIRT1 or inhibition of SIRT2 promotes
neuroprotection in some neurodegenerative mouse
models20. Thus, we analyzed the effect of axotomy of the
hypoglossal nerve on the expression and activity of SIRT1
and SIRT2. SIRT1 was overexpressed in the nuclei of
axotomized MNs at 7 dpi (Fig. 2a). As a measure of its
deacetylase activity, we evaluated levels of histone 3,
which is acetylated at lysine 9 (Ac -H3K9), and p53, which
is deacetylated at lysine 373 (Ac-p53K373), by SIRT1 as
previously reported21, 22. Both acetylated substrates sig-
niﬁcantly accumulated in the nuclei of damaged MNs at 7
dpi when compared to sham-operated control animals
(Fig. 2a). SIRT2 appeared at a characteristic location
probably corresponding to the ER–Golgi intermediate
compartment23, and it was present at lower levels in
axotomized MNs at 7 dpi with respect to the control
(Fig. 2b). Although the total abundance of α-tubulin was
diminished after injury, relative levels of the acetylated
form of α-tubulin were higher than in controls (Fig. 2b).
These results suggest that activities of both SIRT1 and
SIRT2 are reduced early after injury.
We used an in vitro model of ER stress to test whether
an SIRT1 activation and SIRT2 inhibition were neuro-
protective. We used tunicamycin (TUN) as stressor agent
Romeo-Guitart et al. Cell Death and Disease  (2018) 9:531 Page 2 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
Fig. 1 (See legend on next page.)
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on NSC-34 cells, which are MN like. After 24 h, TUN
treatment had induced death of 59.58 ± 1.82% of cells
(Fig. 3a). Overexpression of SIRT1 promoted survival of
ER-stressed cells compared to GFP-overexpressing
insulted cells with only about 20% of cells dead after 24
h of TUN treatment (Fig. 3a). Treatment of ER-stressed
cells with NH, which activates SIRT1 (Fig. S1), was also
protective (Fig. 3a). To analyze effects of SIRT2, we used
AK7, a SIRT2 inhibitor previously reported to exert
neuroprotection in some models of neurodegenerative
diseases. Treatment of the stressed cells with AK7 was
also neuroprotective. We monitored AK7 activity by
analyzing the levels of acetylated H4 at lysine 16 (Ac-
H4K16) (Fig. S2).
We then evaluated effects of administration of these
drugs in vivo. Oral NH treatment in the hypoglossal
axotomy model led to a decrease of Ac-H3K9 levels
within the nucleus of MNs compared to vehicle treatment
(Fig. 3b). Similarly, intraperitoneal (i.p.) AK7 treatment
increased acetylated α-tubulin levels in the hypoglossal
nuclei at 7 dpi with respect to control, as expected for a
SIRT2 inhibitor (Fig. 3c).
These results suggest that NH and AK7 are neuropro-
tective; we used both pharmacological and genetic
approaches to test these hypotheses. Injured animals
treated with NH had an increased percentage of MN
survival than vehicle-treated injured mice (Fig. 4a). Simi-
larly, a higher percentage of MN survival was observed
post injury in transgenic animals overexpressing SIRT1 (tg-
SIRT1)24 compared to injured wild-type (WT) littermates
(Fig. 4a). We also compared survival of MNs in injured
mice that lack SIRT2 (SIRT2 knockout or KO-SIRT2
mice)25 compared to WT littermates with and without
treatment with vehicle or AK7 at 21 dpi (Fig. 4b). Unex-
pectedly, we observed a reduction in the number of sur-
viving MNs in injured KO-SIRT2 mice relative to WT
controls and in injured KO-SIRT2 mice treated with AK7
compared to vehicle-treated mice. Since, SIRT1 activation
or overexpression resulted neuroprotective, we explored
the effect on IRE1α-neuroprotective and ATF6-
neuroprotective UPR branches and found a marked
increase in cleaved ATF6 and its downstream target
GRP78 (Fig. 4c). No signiﬁcant modiﬁcations were
observed regarding IRE1α activation and downstream
XBP1 splicing. These results suggest that inhibition of
SIRT2 is detrimental in vivo, although not in vitro, whereas
fostering SIRT1 activity is beneﬁcial for MN survival after
axotomy of the hypoglossal nerve. Furthermore, SIRT1
activation or overexpression reinforce endogenous
mechanisms of neuroprotection related to UPR.
Due to differences between in vitro and in vivo results
regarding neuroprotection provided by AK7 treatment,
we evaluated this drug in a spinal cord organotypic cul-
ture (SCOC) model26 as we speculated that lack of glial
cells in the culture might be the cause of this discrepancy.
In the SCOC, TUN treatment produced a decline in SMI-
32-positive MN cells compared to untreated or vehicle-
treated SCOCs (Fig. 5a). We observed that TUN treat-
ment drastically reduced the activity of SIRT1 as was the
case for nerve injury in vivo, but in the SCOC, this stress
enhanced the activity of SIRT2 (Figs. S1 and 2). NH
treatment of TUN-treated SCOCs enhanced survival of
MNs, whereas AK7 treatment yielded similar results to
TUN treatment alone (Fig. 5a). Hence, for AK7, the
results obtained in SCOCs were unlike those obtained in
the NSC-34 model but similar to those obtained in the
in vivo model.
Considering that one of the main differences between
the in vitro models is whether or not glia cells are present,
we hypothesized that AK7 inﬂuences this particular cell
type to alter MN destiny. One of the possibilities to be
explored was that AK7 treatment renders microglia more
reactive27. As the transcription factor NF-κB is involved in
the production of pro-inﬂammatory cytokines27, we
investigated its protein levels in the nuclei of microglia in
SCOCs. We did not observe a signiﬁcant increase of NF-
κB in TUN-treated SCOCs compared to levels in vehicle-
treated or control cultures (Fig. 5b). In contrast, there was
a considerable decrease in nuclear NF-κB in the microglia
of NH-treated stressed SCOCs, whereas AK7 treatment
signiﬁcantly increased NF-κB levels in these cultures
(Fig. 5b). Accordingly, levels of interleukin-1β (IL-1β) and
(see ﬁgure on previous page)
Fig. 1 Hypoglossal nerve injury triggers non-apoptotic MN death with activation of IRE1α and XBP1. a (Top) Microphotographs of Fluoro-
Nissl-stained MNs from the ipsilateral hypoglossal nucleus (dotted circled) from HA-injured animals at 7, 14, and 21 dpi. (Bottom left) Drawing
highlighting the hypoglossal nuclei in the brainstem of the mice. (Bottom right) Graphic showing the average percentages ± SEMs of MN survival at
the ipsilateral side with respect to the contralateral after HA at indicated dpi (n= 4 for 14 dpi and n= 5 for other groups; analysis of variances
(ANOVA), post hoc Bonferroni; #p < 0.05 vs. 7 dpi and *p < 0.05 vs. 14 dpi). b (Top panels) Representative images of positive control (C+) from spinal
cord samples of neonatal rats submitted to sciatic crush injury stained for active cleaved caspase-3 (Casp3.Act) merged with Fluoro-Nissl (green) and
DAPI (blue). (Middle and bottom panels) Representative confocal images of MNs from hypoglossal nuclei immunolabeled for Casp3.Act or AIF1m
(red) merged with Fluoro-Jade C-stained hypoglossal nuclei (green) counterstained with DAPI from control (Ctrl) non-injured mice or HA-injured
mice at 7 dpi. Scale bars= 25 μm. c Bar graphs of the expression levels of different UPR-target genes. d Western blots and bar graphs showing the
analysis of phosphorylated IRE1α and PERK, the cleaved fragment of activated ATF6, and spliced (Xbp1s) and unspliced (Xbp1u) XBP1 protein levels in
Ctrl and HA-injured animals at 3 dpi
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Fig. 2 Deacetylase activities of SIRT1 and SIRT2 are reduced after nerve injury. a (Top) Confocal images of MNs immunolabeled for SIRT1, Ac-
H3K9, and Ac-p53K373 (red) and counterstained with Fluoro-Nissl (green) and DAPI (blue) at hypoglossal nuclei of non-injured control (Ctrl) and HA-
injured animals at 7 dpi. Scale bar= 25 µm. (Bottom) Histograms of the means of immunoﬂuorescence densities for each marker inside nuclei of MNs
(n= 4 animals, t test, *p < 0.05 vs. Ctrl). b (Top) Representative confocal microphotographs of SIRT2, α-tubulin (α-Tub), and acetylated α-tubulin (Ac α-
Tub) in red, counterstained with green Fluoro-Nissl and DAPI from hypoglossal nuclei of non-injured or injured animals at 7 dpi. Scale bar= 25 µm.
(Bottom) Histograms of the means of the immunoﬂuorescence densities for each marker inside nuclei of MNs (n= 4 animals, t test, *p < 0.05 vs. Ctrl).
Scale bar= 25 µm and 10 µm for α-Tub and acetyl α-Tub staining
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tumor necrosis factor-α (TNFα) expression were
increased in AK7-treated SCOCs with respect to TUN-
treated or control samples (Fig. 5c).
To conﬁrm that glial cells are critical to MN survival
in vivo, we analyzed AK7-treated injured animals, and we
observed an increase in CD86, a marker of the M1 phe-
notype, in microglial cells treated with AK7 at 3 dpi
(Fig. 6a). We observed signiﬁcantly more NF-κB in the
nucleus of microglia of AK7-treated injured animals than
in controls (Fig. 6b). In addition, we observed an increased
in the expression of IL-1β and TNFα genes upon AK7
treatment (Fig. 6c). Thus, although SIRT2 inhibition
might be beneﬁcial for the neuronal survival itself, effects
on glial cells must also be considered, since the over-
production of pro-inﬂammatory cytokines by glia upon
AK7 treatment might override all beneﬁts to the neurons.
Discussion
Communication between nerve cells or nerve cells and
their target tissue is dysfunctional in neurodegeneration.
Fig. 3 SIRT1 activation by NH and SIRT2 inhibition by AK7 are neuroprotective in ER-stressed NSC-34 MN-like cell culture. a Bar graph
showing the percentages of cells ± SEMs that survived after the treatment with vehicle (Veh) 1 μg/ml tunicamycin (TUN) alone or in combination
with the NeuroHeal or AK7. Percent cell survival was also determined for CMV-SIRT1 and CMV-GFP cells treated with TUN (n= 4–10, analysis of
variances (ANOVA), post hoc Bonferroni #p < 0.05 vs. Veh, *p < 0.05 vs. TUN, $p < 0.05 vs. TUN-GFP). b (Left) Confocal images of H3K9ac (red) in
samples from mice subjected to hypoglossal axotomy and treated with vehicle or NH, counterstained with Fluoro-Nissl (green) and DAPI (blue) at 21
dpi. Scale bar= 25 µm. (Right) Histogram showing the amount of ﬂuorescent density of nuclear H3K9ac in injured MNs in vehicle or NH-treated
groups at 21 dpi (n= 4, t test, *p < 0.05 vs. Veh). c (Left) Microphotographs showing acetylated and total α-tubulin (red) staining with Fluoro-Nissl
(green) and DAPI (blue) counterstaining in animals treated with vehicle or AK7 at 21 dpi. Scale bar= 10 µm. (Right) Histogram showing the ratio of
the acetylated vs. total α-tubulin within the MNs in both groups (n= 4, t test, *p < 0.05 vs. Veh)
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In addition to their particular protein hallmarks, all neu-
rodegenerative diseases are characterized by neuronal cell
death related to soma isolation due to neurite retraction.
Deciphering the programs activated by neurons to cope
with this damage may guide development of neuropro-
tective therapies. The purpose of the present study was to
assess the roles of SIRT1 and SIRT2 in neuroprotection of
disconnected central neurons using the hypoglossal nerve
Fig. 4 SIRT1 and SIRT2 activities are essential for survival of MNs after HA. a (Left) Representative microphotographs of Fluoro-Nissl-stained
ipsilateral hypoglossal nuclei MNs from injured WT mice, tg-SIRT1 mice, or NH-treated WT mice at 21 dpi. Scale bar= 100 µm. (Right) The histogram
represents the mean percentages ± SEMs of surviving MNs in the ipsilateral side respect to the contralateral side (n= 4–5, analysis of variances
(ANOVA), post hoc Bonferroni, *p < 0.05 vs. WT). b (Left) Hypoglossal nuclei stained with Fluoro-Nissl from WT mice, SIRT2-KO mice, and AK7-treated
WT mice (20 mg/kg i.p, daily) at 21 dpi. Scale bar= 100 µm. (Right) Plots of the percentages ± SEMs of the counted MNs at the ipsilateral side respect
the contralateral for different experimental groups at 21 dpi (n= 4, ANOVA, post hoc Bonferroni, *p < 0.05 vs. WT). c Western blots and bar graphs
showing the analysis of phosphorylated IRE1α, the cleaved fragment of activated ATF6, spliced (Xbp1s) and unspliced (Xbp1u) XBP1 and GRP78
protein levels in Ctrl, HA-injured, and NH-treated HA-injured wild-type animals and HA-injured tg-SIRT1 animals at 3 dpi
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axotomy model. Axotomized cranial MNs suffered non-
apoptotic cell death characterized by the activation of the
IRE1α -mediated branch of the UPR that is triggered
during ER stress. We demonstrated that pharmacological
activation of SIRT1 with NH or overexpression of SIRT1
is beneﬁcial, whereas pharmacological or genetic inhibi-
tion of SIRT2 is detrimental for axotomized neuron sur-
vival in vivo. Interestingly, in the face of ER stress, SIRT2
inhibition with AK7 exerted neuroprotection in a moto-
neuron (MN)-like cell line but not in MNs in organotypic
culture. The difference in these two systems is the pre-
sence of glial cells in the latter. AK7 treatment in the
organotypic culture and in the in vivo model promoted
overproduction of pro-inﬂammatory cytokines by micro-
glia that can explain its deleterious effect. In this regard,
neuroinﬂammation disrupted UPR activation under pro-
teasome stress situation28.
We demonstrated that activation of SIRT1 with NH is
important for neuroprotection of disconnected cranial
MNs in mice as it was for root avulsed spinal MNs in
rats5. We recently reported that treatment with NH
produces long-lasting neuroprotection and also accel-
erates nerve regeneration and reduces muscle atrophy in a
pre-clinical model of RA4. We previously showed that
SIRT1 activation was necessary for NH neuroprotection,
although this drug composition targets multiple proteins5.
Fig. 5 SIRT1 and SIRT2 activities maintain neuron survival in an in vitro model of ER stress in SCOCs. a (Left) Representative
microphotographs of ventral horn of the SCOCs stained for SMI-32 after 2 days of treatment with TUN with or without the NH or AK7 co-treatment.
Scale bar= 100 µm. (Right) Bar graphs showing the numbers ± SEMs of SMI-32-positive cells in the ventral horns of each hemisection of the spinal
cord slice (n= 5–10 complete spinal cord slices, analysis of variances (ANOVA), post hoc Bonferroni *p < 0.05 vs. Veh, #p < 0.05 vs. TUN, $p < 0.05 vs.
AK7). b (Left) Confocal microphotographs stained for the p65 subunit of NF-κB (red) and Iba1, a microglia marker (green). Samples were
counterstained with DAPI (blue). Samples from different experimental conditions were stained 6 h after TUN addition. Scale bar= 10 µm. (Right)
Histogram showing the percentages of microglial cells with positive nuclear labeling of NF-κB for each experimental group (n= 4, ANOVA post hoc
Dunnett's test, *p < 0.05 vs. TUN). c Histogram of mean values obtained by quantitative real-time PCR for IL-1β and TNFα mRNA in the control (Ctrl),
TUN, or TUN plus AK7 SCOCs at 6 h post treatment
Romeo-Guitart et al. Cell Death and Disease  (2018) 9:531 Page 8 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
SIRT1 has been shown to be important for neuroprotec-
tion in several models of neurodegenerative diseases (e.g.,
Alzheimer’s disease, Huntington’s disease)29–31 and is
crucial in cerebral ischemia and preconditioning32. We
demonstrated herein that either NH-induced activation or
overexpression of SIRT1 boost endogenous mechanisms
of neuroprotection after injury, as it is the ATF6-GRP78
branch of UPR5. Further future investigations would be
worth doing to unravel the mechanisms underlying this
activation done by SIRT1. Nevertheless, the data shown
here conﬁrm that activation of SIRT1, in particular
through the treatment with NH, is a promising ther-
apeutic option for disconnected neurons.
We expected that AK7 and deletion of SIRT2 would be
neuroprotective since SIRT2 inhibition is reportedly
beneﬁcial in some age-related disorders such as Parkin-
son’s disease12, 33–36 and Huntington disease models37, 38.
In contrast, our results indicated that AK7 treatment was
deleterious for disconnected MN survival in the mouse
model. Although in cell lines the treatment was beneﬁcial,
in the SCOC model, which more accurately reﬂects the
complex microenvironment of the nervous system, AK7
did not enhance MN survival. In our organotypic and
in vivo models, AK7 treatment induced microglia cells to
generate pro-inﬂammatory cytokines, which might over-
ride the treatment-induced protection of neurons. After
axotomy, the primary injury induces inﬂammatory
responses with cytokines and chemokines released into
the peri-lesional areas. Microglial activation, which pro-
pagates inﬂammation into neighboring tissue, may lead to
impaired neuronal survival in the peri-lesional regions as
a result of the generation of cytokines and reactive oxygen
species. Our data indicate that AK7 treatment results in
enhanced microglial activation at the injury site, and this
suggests that SIRT2 inhibition might aggravate the acute
inﬂammatory response. SIRT2 interacts with p65, an NF-
κB subunit, in the cytoplasm and deacetylates lysine 310
in vitro and in vivo39. After TNFα stimulation, p65 is
hyper-acetylated in SIRT2-deﬁcient cells, which results in
increased expression of a subset of p65-target genes39.
This is in agreement with recent reports that indicate that
SIRT2 acetylates p65 to inﬂuence pro-inﬂammatory gene
transcription in microglia40, 26, 8. Together, these data
indicate that post-translational deacetylation of p65 by
SIRT2 might be a mechanism that contributes to its anti-
inﬂammatory properties.
Our results are in agreement with other reports that
AK7 is not beneﬁcial under conditions where the control
of the microglial response is crucial for neuronal survival
such as in amyotrophic lateral sclerosis12 and traumatic
brain injury41. Another study using SIRT2 knockout mice
revealed an increase in microglial activation and pro-
inﬂammatory cytokines upon intracortical injection of
lipopolysaccharide27. SIRT2 deletion also promotes
Fig. 6 SIRT2 inhibition exacerbates microglial reaction and compromises MN survival after HA. a (Left) Microphotographs of samples stained
with CD86 (red), a marker of the M1 phenotype, and Iba (green), a microglia marker, and counterstained with DAPI and Fluoro-Nissl (blues) from
vehicle or AK7-treated HA-injured animals at 3 dpi. Scale bar= 10 μm. (Right) Histogram showing the means ± SEMs of the percentages of microglial
cells with positive CD86 labeling (n= 3 for Veh and n= 4 for AK7, t test, *p < 0.05 vs. Veh). b Histogram showing the means ± SEM of the percentages
of microglial cells with positive nuclear NF-κB labeling (n= 3 for Veh and n= 4 for AK7, t test, *p < 0.05 vs. Veh). c Histogram of mean values obtained
by quantitative real-time PCR for IL-1β and TNFα mRNAs in the hypoglossal nuclei from Veh or AK7-treated animals at 3 dpi
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inﬂammatory responses in a dextran sulfate sodium-
induced model of colitis42. When recombinant SIRT2
protein is transduced into murine macrophages, it inhibits
lipopolysaccharide-induced expression of cytokines as
well as activation of NF-κB and MAPKs43, further
demonstrating a role for SIRT2 activation in the sup-
pression of the inﬂammatory response. However, other
contradictory results imply that SIRT2 might play a det-
rimental role under inﬂammatory conditions. In one
study, SIRT2 inhibition by genetic and pharmacological
mediators resulted in reactive oxygen species production
by macrophages via a mechanism involving degradation of
IκBα and nuclear translocation of p6544, 45. A very
interesting recent study demonstrated that release of
cytokines such as IL-1β and TNFα by classically activated
neuroinﬂammatory microglia induce a subtype of astro-
cytes termed A1-reactive astrocytes that are neurotoxic
for axotomized neurons; these astrocytes are present in
patients with human neurodegenerative diseases46.
Finally, in a totally different way but in agreement to the
detrimental effects of the SIRT2 loss-of-function is a
recent study reporting axonal degeneration observed in
the aged SIRT2-KO mice47.
Overall, the differences in the systems studied might
explain discrepant results. Our data indicate that caution
must be used when extrapolating results obtained in cell
culture systems to therapy design.
Materials and methods
Animals and surgical procedures
The SIRT2−/− C57-BL6 mice were originally generated
by Dr. Qiang Tong at The Human Genetics Institute of
New Jersey (Piscataway Township, NJ, USA)25. Mice with
an extra copy of murine form of SIRT1 gene (tg-SIRT1)
were a kind gift from Dr. Jesús Ruberte (CBATEG, Uni-
versitat Autònoma de Barcelona, Barcelona, Spain). This
transgenic line was generated by Manuel Serrano at the
Tumor Suppression Group, Spanish National Cancer
Research Center in Madrid (Spain) following the protocol
described in Ref. 24.
WT female C57BL/6 (Charles River Laboratories, Wil-
mington, MA, USA) and KO-SIRT2 mice aged 2 months,
and tg-SIRT1 mice weighing an average of 24.92 ± 1.66 g
(Animal Service, Universitat Autònoma de Barcelona),
were maintained under standard conditions of tempera-
ture and light and fed with food and water ad libitum.
Surgical procedures were performed under anesthesia
with ketamine (90 mg/kg, intramuscularly (i.m.)) and
xylazine (10 mg/kg, i.m.). We carried out axotomy of the
hypoglossal nerve as described elsewhere17. Brieﬂy, the
right digastric muscle was opened using blunt-end dis-
section with a pair of scissors, and the right hypoglossal
nerve was exposed. We transected the nerve with a pair of
scissors at the proximal side of the hypoglossal nerve
bifurcation and removed 3mm from the distal stump.
Finally, we separated the nerve stumps to avoid sponta-
neous axon regrowth. The muscle was sutured, and the
wound closed by planes and disinfected with povidone
iodine. The animals were allowed to recover in a warm
environment. NH is composed of acamprosate (Merck,
Darmstadt, Germany) and ribavirin (Normon, Madrid,
Spain)5 For in vivo experiments mice were given these
compounds in drinking water replaced every 3 days. The
concentration of acamprosate was 2.2 mM and that of
ribavirin was 1 mM. AK7 (Sigma-Aldrich, Saint Louis,
MO, USA) was dissolved in Dimethyl sulfoxide (DMSO),
and the stock solution was dissolved in saline. It was
administered at 20 mg/kg i.p. daily. All procedures
involving animals were approved by the ethics committee
of Universitat Autònoma de Barcelona and followed the
European Council Directive 2010/63/EU.
In vitro models
NSC-34 cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium high-glucose (DMEM, Biochrom, Berlin)
supplemented with 10% fetal bovine serum and 1× peni-
cillin/streptomycin solution (Sigma-Aldrich) on collagen-
coated plates (Thermo Fisher, Waltham, MA, USA) in a
humidiﬁed incubator at 37 °C under 5% CO2. We trans-
fected 1 × 106 cells with 2 µg plasmid encoding GFP or
SIRT1 under the control of a cytomegalovirus promoter
using the Amaxa Nucleofector II (Lonza, Norwalk, CT,
USA) and the Nucleofactor V kit (Lonza) following the
manufacturer’s recommendations. After 4 days of cell
culture without changing the medium, cells were differ-
entiated, and freshly prepared drugs diluted in DMEM
were added. For ER stress we added 1 μg/ml TUN (TUN,
Sigma-Aldrich). Treatments with NH (55 μM acampro-
sate and 1 μM ribavirin (Sigma-Aldrich, Saint Louis, MO,
USA) or 25 μM AK7 were performed concomitantly with
TUN treatment. After 24 h, we analyzed cell viability by
incubating the cells with 5 mg/ml 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution
for 4 h at 37 °C and, after medium removal, the MTT salts
were dissolved in DMSO. After 5 min, absorbance at 570
nm was measured with a Biotek Elx800 microplate reader
(Winooski, VT, USA). The percentage of surviving cells
was obtained by comparing each group with the absor-
bance value derived from control on each plate.
We prepared SCOCs from lumbar sections of 8-day-old
Sprague–Dawley pups as previously described26. Brieﬂy,
we collected the spinal cords from the pups and placed
them into cold high-glucose-containing (6.4 mg/ml) Gey’s
balanced salt solution (Sigma-Aldrich, Steinheim, Ger-
many). After removing the meninges and roots, we cut
spinal cords into 350-μm transverse sections with a
McIlwain Tissue Chopper. Four lumbar sections were
transferred onto 30-mm diameter, 0.4-μm Millicell-CM
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nets (Millipore, Billerica, MA, USA) in 6-well plates
(Thermo Fisher Scientiﬁc) containing 1ml of medium
(50% (v/v) minimal essential medium, 2mM glutamine, 25
(v/v) Hank’s balanced solution (Sigma-Aldrich) supple-
mented with 25.6mg/ml glucose and 25mM HEPES, pH
7.2). Cultures were maintained at 37 °C in a 5% CO2
humidiﬁed environment. The medium was unchanged
during the ﬁrst week of culture and was then changed
twice per week. After 15 days, we added 1 μg/ml TUN
alone or in combination with NH or AK7. At 6 h and at
2 days post treatment, we ﬁxed the SCOCs with 4% par-
aformaldehyde in a 0.1M phosphate buffer (pH 7.2) for 1 h
at room temperature. We washed the SCOCs with 0.3%
Triton X-100 in Tris-buffered saline (TBS; 50mM Tris,
pH 7.6, 150mMNaCl) solution. SCOCs were blocked with
10% normal donkey serum in TBS and incubated 2 days
with mouse anti-SMI-32 (1:1000; Biolegend, San Diego,
CA, USA) at 4 °C. Then, we washed the SCOCs with 0.1%
Tween-20 in TBS solution and incubated with Alexa 488-
conjugated donkey anti-mouse antibodies (1:200; Jackson
Immunoresearch, West Grove, PA, USA) for 2 h at room
temperature. After several washes, we counterstained with
4',6-diamidino-2-phenylindole (DAPI) and mounted with
Fluoromount-G mounting medium (SouthernBiotech,
Birmingham, AL, USA). Samples were photographed with
an Olympus DP76 digital camera (Olympus, Shinjuku,
Tokyo, Japan) attached to the microscope (Olympus
BX51). MN survival was assessed by counting all SMI-32-
positive neurons at the ventral horn for each spinal cord
hemisection. Six different SCOCs were used for each
experimental condition.
Immunohistochemistry and image analysis
After deep anesthesia with pentobarbital, we transcar-
dially perfused the animals with a saline solution con-
taining 10 U/ml heparin, followed by 4%
paraformaldehyde in a 0.1M phosphate buffer, pH 7.2, for
tissue ﬁxation at 3, 7, or 21 dpi (n= 4 for each condition).
Brainstems were removed and post-ﬁxed in the same
buffer overnight at 4 °C hours and cryopreserved in 30%
sucrose until processed. We isolated the brainstem zone
containing the hypoglossal nuclei using a brain mold, and
we cut it into serial transversal sections (10 µm thick) with
the aid of a cryotome (Leica, Heidelberg, Germany) on
gelatinized slides and preserved them at −20 °C until use.
For neonatal rats, we perfused them as explained pre-
viously at 10 dpi, extracted the L4–L6 spinal cord seg-
ment, and cut it into transversal serial sections of 20 µm
thick. We treated the brainstem spinal cord or SCOC
slides with TBS with 0.3% Triton X-100 and 10% bovine
serum for 1 h and incubated them with the following
primary antibodies: rabbit anti-Iba1 (1:1000, Wako,
Osaka, Japan), rabbit anti-SIRT1 (1:100, Millipore), rabbit
anti-Ac-H3K9 (1:50, Millipore), rabbit anti-Ac-p53K373
(1:500, Millipore), rabbit anti-SIRT2 (1:200, Sigma-
Aldrich), mouse anti-α-tubulin (1:500; Sigma-Aldrich),
mouse anti-acetylated α-tubulin (1:500; Hybridoma Bank,
Iowa City, IA, USA), mouse anti-anti-SMI-32 (1:1000;
Biolegend), rabbit anti-p65 (1:1000, Cell Signaling, Dan-
ver, MA, USA), rat-anti-CD86 (1:200; BD Biosciences, San
Jose, CA, USA), rabbit anti-Casp3.Act (1:200; Cell Sig-
naling), and rabbit anti-AIF1 (1:200; Antibodies-Online,
Atlanta, GA, USA). After several washes with 0.1%
Tween-20 in TBS solution, the sections were incubated
for 2 h with donkey anti-rabbit or anti-mouse antibodies
(1:200; Jackson Immunoresearch) conjugated to Cy-3, Cy-
2, Alexa 488, or Alexa 594 and washed with 0.3% Triton
X-100 in TBS. We counterstained the sections with DAPI
(Sigma-Aldrich) or NeuroTrace Fluorescent Nissl Stain
(Molecular Probes, Leiden, Netherlands) and mounted
sections with Fluoromount-G mounting medium
(SouthernBiotech). Sections to be compared were pro-
cessed together on the same slide and on the same day.
Images from sections of different treatments and controls
were taken under the same exposure time, sensitivity, and
resolution for each analyzed marker.). Confocal images
were obtained using two separate photomultiplier chan-
nels with a 1.4 numerical aperture oil-immersion objec-
tive of ×20 or ×40. Images were separately projected and
merged using a pseudocolor display. We analyzed ﬂuor-
escence signal intensity using the ImageJ software
(National Institutes of Health, Bethesda, MD, USA;
available at http://rsb.info.nih.gov/ij/). The analysis of the
images to be compared was performed the same day. We
delimited an area as region of interest (ROI) with the aid
of Fluoro-Nissl labeling for MN cytoplasm or DAPI for
MN nuclei. The integrated density inside the ROI was
obtained for at least 15 MNs/animal per marker from
three 100-μm sections from distant regions.
Fluoro-Jade C staining
Brainstem sections were randomly selected and stained
with Fluoro-Jade C (Chemicon, Tokyo, Japan) following the
manufacturer’s protocol. In brief, the slices were immersed
in a solution of 80% EtOH with 1% of NaOH for 5min, then
rinsed for 2min in 70% EtOH and 2min in distilled water,
and incubated for 10min with 0.06% permanganate solu-
tion. After washing with water, the slices were transferred to
a solution of 0.0001% of Fluoro-Jade C dissolved in 0.1%
acetic acid and were incubated for 10min. Then, the slices
were washed with water, counterstained with DAPI, and
mounted with dibutylphthalate polystyrene xylene (Sigma).
Confocal images were taken within several hours of the
staining to avoid ﬂuorescence loss.
Motor neuron counting
Sixteen brainstem sections separated by at least 50 μm
and including the hypoglossal nuclei were randomly
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selected and stained with Fluorescent Neurotracer (Life
Technologies, Carlsbad, CA, USA) following the manu-
facturer’s protocol. Sequential microphotographs from
the injured and contralateral MN hypoglossal were taken
using an Olympus DP76 digital camera attached to the
microscope (Olympus BX51). The MNs with diameters
>17 μm (area of 320 μm2)
48, 49, prominent nucleous,
polygonal shape, and located in the hypoglossal nucleus
were counted. For comparisons, the percentage of MN
survival was calculated by comparison to numbers at the
injured site with numbers at the contralateral site for each
section.
Western blot
Control and HA-injured mice with or without NH
treatment at 3 dpi (n= 4 per group) were deeply anes-
thetized with pentobarbital, and whole brain tissue was
obtained for western blot analysis. Samples were snap
frozen in liquid nitrogen. Hypoglossal nuclei were
removed and homogenized in lysis buffer (20 mM HEPES,
pH 7.2, 250mM sucrose, 1 mM EDTA, 1 mM EGTA, and
a cocktail of protease (Sigma) and phosphatase inhibitors
(Roche, Manheim, Germany)) using a Potter homogenizer
on ice. The lysate was centrifuged for 20min at 800 × g at
4 °C, and the supernatant (the cytosolic fraction) was
collected. The pellet was mixed with nuclear buffer (20
mM HEPES, pH 7.2, 0.1% Triton X-100, 0.2 mM EGTA,
0.2 mM EDTA, 1M KCl, and a cocktail of protease
(Sigma) and phosphatase inhibitors (Roche)) by vortexing
at 1400 rpm for 20min at 4 °C. After centrifuging at
10,000 × g for 10 min at 4 °C, the supernatant was col-
lected (the nuclear fraction). Finally, we quantiﬁed the
amount of protein in cytosolic and nuclear fractions using
the BCA assay (Pierce Chemical Co., Rockford, IL, USA).
For western blotting, we mixed equal amounts of samples
from four animals and loaded 10 μg of cytosolic or nuclear
fractions onto a 10% sodium dodecyl sulfate-
polyacrylamide gel. After electrophoretic separation of
proteins and transfer to a PVDF membrane in a Bio-Rad
Cubette System (Bio-Rad Laboratories, Hercules, CA,
USA) in 25mM Tris, pH 8.4, 192 mM glycine, and 20%
(v/v) methanol. After blocking with TBS, 0.1% Tween-20,
5% milk, the membrane was incubated overnight at 4 °C
with the primary antibody: rabbit anti-IRE1α (1:1000),
rabbit anti-XBP1 (1:1000), rabbit anti-phosphor-PERK
(pPERK,1:1000), rabbit anti-PERK (1:1000) (Cell Signal-
ing, Denvers, MA, USA), rabbit anti-ATF6 (1:1000, Santa
Cruz Biotech, Santa Cruz, CA, USA), or GRP78 (1:1000,
Stressgen Biotechnologies, Victoria, BC, Canada). The
following day, membranes were washed and then incu-
bated for 1 h with an appropriate secondary antibody
conjugated with horseradish peroxidase (1:5000, Vector
Laboratories, Burlingame, CA, USA) at room tempera-
ture. Proteins were developed using a chemiluminescence
method (ECL Clarity Kit, Bio-Rad Laboratories), and the
images were captured and analyzed with Image Lab
Software (Bio-Rad Laboratories).
RNA extraction, reverse transcription, and real-time PCR
For PCR analysis, total RNA was extracted using the
Tripure Isolation Reagent (Roche) according to the
instructions of the manufacturer. Reverse transcription
was performed using random hexamers primers exactly as
previously described50. PCR was performed in an ABI
Prism 7000 sequence detector (Applied Biosystems,
Madrid, Spain) using cDNA diluted in sterile water as
template. TNFα, IL-1β, Grp78, and the control house-
keeping genes were ampliﬁed using speciﬁc Taqman
probes supplied by Applied Biosystems. Some primers
were used to amplify Chop (forward (F): 5′-CCCCAG-
GAAACGAAGAGGAAGAATC-3′; reverse (R): 5′-CTA
CCCTCAGTCCCCTCCTCAGCAT-3′), Xbp1total (F: 5′-
GCTTGTGATTGAGAACCAGG-3′; R: 5′-GAGGCTT
GGTGTATACATGG-3′), and Xbp1s (mix of F: 5′-GCT
TGTGATTGAGAACCAGG-3′; R: 5′-GGCCTGCA
CCTGCTGCGGACTC-3′ and F: 5′-GAGTCCGCAG-
CAGGT-3′; R: 5′- GAGGCTTGGTGTATACATGG-3′).
Threshold cycle (Ct) values were calculated using the
software supplied by Applied Biosystems.
Statistical analyses
All data are presented as means ± standard errors of the
means. The statistical analysis was performed with
GraphPad Prism 5 software (San Diego, CA, USA) using
unpaired t test (one or two tailed) or one-way analysis of
variance followed by Bonferroni’s multiple test. Differ-
ences were considered signiﬁcant at p < 0.05.
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